Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 4:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 817–840 of 2,209 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control I Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Feasibility of Insomnia Tracking and Treatment in IBD

NCT04132024
View directory record Official record
Conditions
Inflammatory Bowel Diseases, Insomnia
Interventions
Cognitive Behavioral Therapy for Insomnia (CBT-I)
Behavioral
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
Not listed
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated May 11, 2021 · Synced Oct 29, 2026, 4:40 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Pathophysiology of Orthostatic Intolerance

NCT00608725
View directory record Official record
Conditions
Tachycardia, Postural Orthostatic Tachycardia Syndrome
Interventions
DAXOR, QSweat, Intrinsic Heart Rate
Radiation · Procedure · Drug
Lead sponsor
Satish R. Raj
Other
Eligibility
18 Years to 80 Years
Enrollment
260 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1996 – 2029
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 29, 2026, 4:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Understand the Safety, Tolerability, and Activity of Drug in Body Over a Period of Time of AZD2693, in Subjects of Non-Childbearing Potential in Overweight But Otherwise Healthy Subjects, and Healthy Chinese and Japanese Subjects

NCT04142424
View directory record Official record
Conditions
Metabolic Disorders, Non-alcoholic Steatohepatitis
Interventions
AZD2693, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Nov 26, 2021 · Synced Oct 29, 2026, 4:40 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Rebif Advanced Magnetic Resonance Imaging (MRI) and Immunology Pilot Trial

NCT01085318
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Rebif
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Rockland, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 23, 2018 · Synced Oct 29, 2026, 4:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluation of Photosafety of BI 730357 Compared to Placebo and the Known Photosensitizing Agent Ciprofloxacin

NCT04147260
View directory record Official record
Conditions
Healthy
Interventions
BI 730357, Placebo to match BI 730357, Ciprofloxacin
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 55 Years
Enrollment
85 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Fair Lawn, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 17, 2023 · Synced Oct 29, 2026, 4:40 PM EDT
Withdrawn Phase 1 Interventional

Peptide-Pulsed Dendritic Cell Vaccination in Combination With Nivolumab and Ipilimumab for the Treatment of Recurrent and/or Progressive Diffuse Hemispheric Glioma, H3 G34-mutant

NCT05457959
View directory record Official record
Conditions
Diffuse Hemispheric Glioma, H3 G34-Mutant
Interventions
Dendritic Cell Tumor Peptide Vaccine, Ipilimumab, Leukapheresis, Nivolumab, Placebo Administration, Poly ICLC, Resection
Biological · Procedure · Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
13 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 24, 2025 · Synced Oct 29, 2026, 4:40 PM EDT
Not listed Phase 2 Interventional

SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma (SURVIVE)

NCT05163080
View directory record Official record
Conditions
Newly Diagnosed Glioblastoma
Interventions
SurVaxM
Biological
Lead sponsor
MimiVax, LLC
Industry
Eligibility
18 Years and older
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
11
States / cities
San Francisco, California • Miami, Florida • Louisville, Kentucky + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2024 · Synced Oct 29, 2026, 4:40 PM EDT
Active, not recruiting Not applicable Interventional

I-CARE 2: Mobile Telehealth to Reduce Alzheimer'S-related Symptoms in Hispanic Individuals

NCT06099197
View directory record Official record
Conditions
Caregiver Burden, Alzheimer Disease
Interventions
Brain CareNotes, Dementia Guide Expert
Behavioral
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Bloomington, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 29, 2026, 4:40 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Aggressive Driving and Road Rage: A Driving Simulation Experiment.

NCT03430973
View directory record Official record
Conditions
Aggression
Interventions
Videos, Bumper stickers, Alcohol-related cues, Music, Roadside vegetation, Video game
Behavioral
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2025
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 19, 2025 · Synced Oct 29, 2026, 4:40 PM EDT
Suspended Phase 2 Interventional

Ampligen Combined With SOC Versus SOC Alone Following First-Line Therapy in Subjects With LAPC

NCT05494697
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Rintatolimod
Drug
Lead sponsor
AIM ImmunoTech Inc.
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2031
U.S. locations
3
States / cities
Omaha, Nebraska • Canton, Ohio • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 29, 2026, 4:40 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CHK-336 in Healthy Volunteers

NCT05367661
View directory record Official record
Conditions
Healthy Volunteers
Interventions
CHK336, Placebo
Drug
Lead sponsor
Chinook Therapeutics, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 3, 2023 · Synced Oct 29, 2026, 4:40 PM EDT
Completed Not applicable Interventional Results available

Sleep Chatbot Intervention for Emerging Black/African American Adults

NCT05956886
View directory record Official record
Conditions
Sleep Deprivation, Insomnia, Metabolic Syndrome
Interventions
sleep chatbot
Behavioral
Lead sponsor
University of Delaware
Other
Eligibility
18 Years to 25 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 29, 2026, 4:40 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Expressive Writing in Improving the Wellbeing or Comforting Capacity of Caregivers of Patients With Cancer

NCT02339870
View directory record Official record
Conditions
Caregiver
Interventions
Psychosocial Support for Caregiver, Questionnaire Administration, Sham Intervention
Other
Lead sponsor
University of Washington
Other
Eligibility
19 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 15, 2016 · Synced Oct 29, 2026, 4:40 PM EDT
Completed Phase 2 Interventional Results available

PROSTVAC (PSA-TRICOM) in Preventing Disease Progression in Patients With Localized Prostate Cancer Undergoing Active Surveillance

NCT02326805
View directory record Official record
Conditions
Stage I Prostate Adenocarcinoma AJCC v7, Stage II Prostate Adenocarcinoma AJCC v7
Interventions
Laboratory Biomarker Analysis, Placebo Administration, Rilimogene Galvacirepvec
Other · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Male only
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
7
States / cities
Los Angeles, California • Newport Beach, California • Orange, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2023 · Synced Oct 29, 2026, 4:40 PM EDT
Completed Phase 3 Interventional Results available

Study of the Efficacy and Safety of Alirocumab (REGN727/SAR236553) in Combination With Other Lipid-modifying Treatment (LMT) (ODYSSEY OPTIONS I)

NCT01730040
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Alirocumab, Atorvastatin, Ezetimibe, Rosuvastatin, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
355 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
56
States / cities
Mobile, Alabama • Chandler, Arizona • Tucson, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2015 · Synced Oct 29, 2026, 4:40 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Clinical Trial of Autologous Oxidized Tumor Cell Lysate Vaccine For Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer

NCT01312389
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Interventions
OC-L/Montanide ISA 51 VG, Ampligen, Prevnar
Biological
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 15, 2021 · Synced Oct 29, 2026, 4:40 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Latino MSM Focused Pre-Exposure Prophylaxis Uptake Intervention

NCT05434390
View directory record Official record
Conditions
HIV
Interventions
Estoy PrEParado/ I am PrEPared intervention, Usual Care
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older · Male only
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 29, 2026, 4:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

H5N8 Mix and Match With or Without AS03 or MF59 in Healthy Adults: Immunology

NCT03014310
View directory record Official record
Conditions
Avian Influenza
Interventions
AS03, MF59, Monovalent Influenza A/H5N8 vaccine
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
19 Years to 64 Years
Enrollment
388 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
7
States / cities
Atlanta, Georgia • Baltimore, Maryland • St Louis, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2024 · Synced Oct 29, 2026, 4:40 PM EDT
Completed Not applicable Interventional

An Evaluation of the PureWick™ Male External Catheter Versus an Established Comparator Overnight in the Home Setting for Incontinence in Adult Males

NCT07282860
View directory record Official record
Conditions
Urinary Incontinence
Interventions
PureWick System, UltraFlex Self-Adhering Male External Catheter
Device
Lead sponsor
C. R. Bard
Industry
Eligibility
18 Years and older · Male only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
15
States / cities
Guntersville, Alabama • Tucson, Arizona • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 29, 2026, 4:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety Study of Single Administration Post-Exposure Prophylaxis Treatment for Ebola Virus

NCT01353027
View directory record Official record
Conditions
Ebola Hemorrhagic Fever
Interventions
Placebo, AVI-6002
Drug
Lead sponsor
Sarepta Therapeutics, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 28, 2012 · Synced Oct 29, 2026, 4:40 PM EDT
Terminated Not applicable Interventional

Feasibility of Auricular Acupressure for Appetite and Weight in Patients With Stage II-IV Gastric, Esophageal, and Pancreatic Cancer

NCT05911243
View directory record Official record
Conditions
Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage II Gastric Cancer AJCC v8, Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage IV Esophageal Adenocarcinoma AJCC v8, Clinical Stage IV Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
Interventions
Acupressure Therapy, Best Practice, Biospecimen Collection, Questionnaire Administration
Procedure · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 29, 2026, 4:40 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study Evaluating the Safety and Preliminary Efficacy of sFilm-FS in Controlling Parenchymal Bleeding During Elective Hepatic Surgery

NCT04660721
View directory record Official record
Conditions
Hemostasis, General Surgery
Interventions
sFilm-FS, TACHOSIL®
Combination Product
Lead sponsor
Sealantium Medical Ltd.
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 21, 2025 · Synced Oct 29, 2026, 4:40 PM EDT
Recruiting Not applicable Interventional

An Automated Personalized Physical Activity Intervention to Improve Immune Function and Clinical Outcomes in Stage II-IV Ovarian, Primary Peritoneal or Fallopian Tube Cancer and Newly Diagnosed Endometrial Cancer, Life on the Go 3 Study

NCT06855706
View directory record Official record
Conditions
Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Stage II Fallopian Tube Cancer AJCC v8, Stage II Ovarian Cancer AJCC v8, Stage II Primary Peritoneal Cancer AJCC v8, Stage III Fallopian Tube Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Primary Peritoneal Cancer AJCC v8, Stage IV Fallopian Tube Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Primary Peritoneal Cancer AJCC v8
Interventions
Behavioral Intervention, Best Practice, Biospecimen Collection, Electronic Health Record Review, Exercise Intervention, Medical Device Usage and Evaluation, Questionnaire Administration, Supportive Care
Behavioral · Other · Procedure
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Oct 29, 2026, 4:40 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Cerebral GABA and Fear Conditioning in PTSD

NCT01800383
View directory record Official record
Conditions
Stress Disorders, Post-Traumatic
Interventions
Not listed
Lead sponsor
Isabelle Rosso
Other
Eligibility
20 Years to 50 Years
Enrollment
126 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2022
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 4, 2023 · Synced Oct 29, 2026, 4:40 PM EDT